Current atherosclerosis reportsOct 15, 2026

GLP-1 Receptor Drugs and Lipoprotein (a): Understanding Their Role and Importance in Heart Diseases

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 16, 2026

Abstract

Lipoprotein(a) [Lp(a)] is a well-established independent risk factor for cardiovascular disease.

Lp(a) is predominantly genetically determined and remains stable throughout life.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown broad cardiometabolic benefits.
The influence of GLP-1RAs on Lp(a) levels is currently unclear.
This review highlights recent evidence linking GLP-1RAs, Lp(a), and cardiovascular disease.
Mechanistic pathways related to GLP-1RAs and their potential effects on cardiovascular risk are examined.

Simplified

Lipoprotein(a) [Lp(a)], a predominantly genetically determined biomarker that remains relatively stable throughout life, is a well-established and independent risk factor for cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated broad cardiometabolic benefits, yet their potential influence on Lp(a) remains unclear. This review synthesizes the most recent evidence at the intersection of GLP-1RAs, Lp(a), and cardiovascular disease, with particular emphasis on underlying mechanistic pathways and their potential implications for cardiovascular risk stratification and clinical outcomes.

Full Text

Full text is available at the source.

View Full Text ↗

GLP-1 Receptor Drugs and Lipoprotein (a): Understanding Their Role and Importance in Heart Diseases

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief